Pages that link to "Q40266380"
Jump to navigation
Jump to search
The following pages link to Rare essentials: drugs for rare diseases as essential medicines (Q40266380):
Displaying 34 items.
- Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries (Q26785430) (← links)
- Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives (Q27005639) (← links)
- Adopting an orphan. (Q34360362) (← links)
- Orphan drug: Development trends and strategies (Q34373817) (← links)
- A vertex similarity-based framework to discover and rank orphan disease-related genes (Q34529478) (← links)
- Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework (Q35126801) (← links)
- Evaluating the quality and use of economic data in decisions about essential medicines (Q35851002) (← links)
- DIGNiFI: Discovering causative genes for orphan diseases using protein-protein interaction networks (Q36329373) (← links)
- Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes (Q36573038) (← links)
- Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs (Q36675654) (← links)
- Determinants and Equity Evaluation for Health Expenditure Among Patients with Rare Diseases in China. (Q37011311) (← links)
- Systematic review of available evidence on 11 high-priced inpatient orphan drugs. (Q37116422) (← links)
- Selective screening for lysosomal storage diseases with dried blood spots collected on filter paper in 4,700 high-risk colombian subjects (Q37127624) (← links)
- Predictors of orphan drug approval in the European Union (Q37157382) (← links)
- The End-of-Life Experience of Patients With Rare Cancers and Their Caregivers (Q37687391) (← links)
- Characteristics of orphan drug applications that fail to achieve marketing approval in the USA (Q37811373) (← links)
- Prioritization of orphan disease-causing genes using topological feature and GO similarity between proteins in interaction networks (Q38422071) (← links)
- Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe? (Q38611154) (← links)
- Essential Medicines List Implementation Dynamics: A Case Study Using Brazilian Federal Medicines Expenditures (Q38858834) (← links)
- Homozygous mutation of STXBP5L explains an autosomal recessive infantile-onset neurodegenerative disorder (Q41694710) (← links)
- The orphan disease networks (Q41807086) (← links)
- Health care resource utilization and cost of care for haemophilia A and B patients in Iran (Q45882975) (← links)
- Issues on Luck Egalitarianism, Responsibility, and Intercultural Healthcare Policies. (Q47803324) (← links)
- Realising the right to sexual and reproductive health: access to essential medicines for medical abortion as a core obligation (Q48121510) (← links)
- Progress in Rare Diseases Research 2010-2016: An IRDiRC Perspective (Q49442680) (← links)
- Navigating through orphan medicinal product regulations in EU and US--similarities and differences (Q50602334) (← links)
- European regulation on orphan medicinal products: 10 years of experience and future perspectives (Q51711644) (← links)
- A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy (Q51894555) (← links)
- Difficulties in the diagnosis and treatment of rare diseases according to the perceptions of patients, relatives and health care professionals. (Q52325051) (← links)
- Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy (Q57001135) (← links)
- Phenotype-Driven Virtual Panel Is an Effective Method to Analyze WES Data of Neurological Disease (Q61449916) (← links)
- World Health Organization program for the selection and use of essential medicines (Q64046001) (← links)
- The essential medicines list for a global patient population (Q81475632) (← links)
- Fullerene as a doxorubicin nanotransporter for targeted breast cancer therapy: Capillary electrophoresis analysis (Q89184887) (← links)